Matinas BioPharma Holdings, Inc. (MTNB): Capital Expenditures

Annual figures by period end, from SEC filings.

Older than the company's other figures. The latest Capital Expenditures is for the year ended 2023-12-31, while the company's latest annual report covers the year ended 2025-12-31. Its later filings do not report this line under the concept TickerFacts maps.

$218.0K
Year ended 2023-12-31
+236.0%
3-year compound annual growth
-16.5%
5-year compound annual growth
+8.8%
10-year compound annual growth
$942.2K2013-12-31: $94.2K2014-12-31: $288.5K2015-12-31: $76.2K2016-12-31: $02017-12-31: $942.2K2018-12-31: $535.9K2019-12-31: $405.6K2020-12-31: $5.7K2021-12-31: $260.0K2022-12-31: $892.0K2023-12-31: $218.0K$218.0K
2013-12-31 Capital Expenditures (USD) 2023-12-31
Period endedCapital ExpendituresChange YoYSource filing
2023-12-31$218.0K-75.6%2025-04-15, From 2023-01-01
2022-12-31$892.0K+243.1%2024-03-27, From 2022-01-01
2021-12-31$260.0Kn/m2023-03-15, From 2021-01-01
2020-12-31$5.7K-98.6%2022-03-11, From 2020-01-01
2019-12-31$405.6K-24.3%2021-03-29, From 2019-01-01
2018-12-31$535.9K-43.1%2020-03-09, From 2018-01-01
2017-12-31$942.2Kn/a2019-04-01, From 2017-01-01
2016-12-31$0-100.0%2017-03-31, From 2016-01-01
2015-12-31$76.2K-73.6%2018-03-16, From 2015-01-01
2014-12-31$288.5K+206.3%2016-03-30, From 2014-01-01
2013-12-31$94.2Kn/a2015-03-31, From 2013-01-01